All In Biotech

Drug Trial Radar · NCT00090103

Benign Prostatic Hyperplasia Trial With Dutasteride And Tamsulosin Combination Treatment

A Randomized, Double-blind, Parallel Group Study to Investigate the Efficacy and Safety of Treatment With Dutasteride (0.5mg) and Tamsulosin (0.4mg), Administered Once Daily for 4 Years, Alone and Combination, on the Improvement of Symptoms and Clinical Outcome in Men With Moderate to Severe Symptomatic Benign Prostatic Hyperplasia

Last checked: Nov 20, 2026Latest source record: Feb 28, 2017 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. Randomized with 4,844 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

4,844

Actual

Start

Nov 2003

Primary completion

Apr 2009

Study completion Apr 2009

Sponsor

Lead sponsor
GlaxoSmithKlineGSK (GSK)
Sponsor type
Industry
First posted
Aug 26, 2004

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Double (participant, investigator)
Primary purpose
Treatment
Who can join
Male only, from 50 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This study will investigate the efficacy and safety of treatment with dutasteride and tamsulosin, administered once daily for 4 years, alone and in combination, on the improvement of symptoms and clinical outcome in men with moderate to severe symptomatic Benign Prostatic Hyperplasia (BPH). Study visits are every 3 months for up to 4 years (18 clinic visits). Transrectal ultrasound (TRUS) is done annually.

Conditions

  • Prostatic Hyperplasia

Interventions

  • dutasteride 0.5mg once daily for 4 yearsDrug

    combination or single agent

  • tamsulosin 0.4mg once daily for 4 yearsDrug

    combination agent or single agent

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Number of Events of Acute Urinary Retention (AUR) or Benign Prostatic Hyperplasia (BPH)-Related Prostatic Surgery at the Indicated Time Periods.Time frame: Years 1, 2, 3, and 4
  2. Number of Participants With AUR or BPH-related SurgeryTime frame: Baseline (Day 1) through Year 4

Locations

503 sites in 36 countries. Site status is shown where the registry gives one.

  • GSK Investigational Site

    Birmingham, Alabama

  • GSK Investigational Site

    Birmingham, Alabama

  • GSK Investigational Site

    Birmingham, Alabama

  • GSK Investigational Site

    Birmingham, Alabama

  • GSK Investigational Site

    Columbiana, Alabama

  • GSK Investigational Site

    Hoover, Alabama

  • GSK Investigational Site

    Anchorage, Alaska

  • GSK Investigational Site

    Phoenix, Arizona

  • GSK Investigational Site

    Phoenix, Arizona, Arizona

  • GSK Investigational Site

    Beverly Hills, California

  • GSK Investigational Site

    Concord, California

  • GSK Investigational Site

    Glendora, California

  • GSK Investigational Site

    Greenbrae, California

  • GSK Investigational Site

    Irvine, California

  • GSK Investigational Site

    La Jolla, California

  • GSK Investigational Site

    Laguna Woods, California

  • GSK Investigational Site

    Los Angelas, California

  • GSK Investigational Site

    Los Angeles, California

  • GSK Investigational Site

    Los Angeles, California

  • GSK Investigational Site

    Modesto, California

  • GSK Investigational Site

    Sacramento, California

  • GSK Investigational Site

    San Diego, California

  • GSK Investigational Site

    San Diego, California

  • GSK Investigational Site

    San Diego, California

  • GSK Investigational Site

    Torrance, California

  • GSK Investigational Site

    Vista, California

  • GSK Investigational Site

    Aventura, Florida

  • GSK Investigational Site

    Bay Pines, Florida

  • GSK Investigational Site

    Coral Gables, Florida

  • GSK Investigational Site

    Daytona Beach, Florida

  • GSK Investigational Site

    Lake Worth, Florida

  • GSK Investigational Site

    Miami, Florida

  • GSK Investigational Site

    New Smyrna Beach, Florida

  • GSK Investigational Site

    Ocala, Florida

  • GSK Investigational Site

    Orange City, Florida

  • GSK Investigational Site

    Pensacola, Florida

  • GSK Investigational Site

    Pinecrest, Florida

  • GSK Investigational Site

    Saint Augustine, Florida

  • GSK Investigational Site

    Spring Hill, Florida

  • GSK Investigational Site

    St. Petersburg, Florida

Showing 40 of 503 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.